Treatment Optimization Pillar
Aligning Industry Incentives with AMR Control Goals: Exploring the Feasibility of an Antibiotic Susceptibility Bonus for Drugs to Treat Gram-negative Infection
Project Key Words: Antimicrobial Resistance, Antibiotics, Incentives, Pharmaceutical Industry
Principal Investigator: Aidan Hollis, PhD
Co-Investigator(s): Stephan Harbarth, MD; Olof Lindahl, PhD
Trainees: Javad Moradpour, MA
Project Theme: Policy, Economics & Sustainability
Large new financial incentives to accelerate antibiotic research and development are being considered. The proposed Antibiotic Sustainability Bonus would make some part of those payments conditional on sustained pathogen susceptibility.
Why is This Important?
Appropriate incentives will help direct research to antimicrobials that have sustained effectiveness, and help companies to support stewardship.
The feasibility of this approach is not currently known.
Research papers that help guide government policy around market entry rewards for novel antibiotics.
Leveraged Sources of Support
- This project is funded under the JPIAMR in collaboration with CIHR.
Knowledge & Technology Exchange and Exploitation
- We hope that this project will help to inform policy around "market entry rewards" for new antibiotics.
Highly Qualified Personnel
- 1 PhD student